---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-230786"
form_type: "8-K"
ticker: "ANTX"
cik: "0001880438"
company_name: "AN2 Therapeutics, Inc."
filed_at: "2023-09-08T23:59:59+00:00"
generated_at: "2026-06-10T22:21:09.667772+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# AN2 Therapeutics appoints CFO Lucy Day as Principal Accounting Officer; VP Controller departs

## Summary
- Lucy Day, current CFO, adds role of Principal Accounting Officer effective September 1, 2023.
- Michael Nazak, Vice President & Corporate Controller, to depart on September 15, 2023.
- Annie Yoshiyama hired as new Vice President, Finance and Corporate Controller.

## SEC filing metadata
- accession: 0001193125-23-230786
- form_type: 8-K
- ticker: ANTX
- cik: 0001880438
- company_name: AN2 Therapeutics, Inc.
- filed_at: 2023-09-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1880438/000119312523230786/0001193125-23-230786-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1880438/000119312523230786/d514862d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-230786
- JSON: https://secwatch.observer/filing/0001193125-23-230786.json
- Plain text: https://secwatch.observer/filing/0001193125-23-230786.txt

## Key facts
- Executive change
  Lucy Day was appointed as Principal Accounting Officer at AN2 Therapeutics, Inc..
  - Action: appointed
  - Role: Principal Accounting Officer
  source text: On September 1, 2023, the Company’s Board of Directors appointed Lucy Day, the Company’s current Chief Financial Officer and Principal Financial Officer, to also serve as the Company’s Principal Accounting Officer effective as of September 1, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1880438/000119312523230786/0001193125-23-230786-index.htm
- Executive change
  Annie Yoshiyama was appointed as Vice President, Finance and Corporate Controller at AN2 Therapeutics, Inc..
  - Action: hired
  - Role: Vice President, Finance and Corporate Controller
  source text: The Company has hired Annie Yoshiyama, previously Senior Vice President, Finance and Chief Accounting Officer at Tricida, Inc., as its new Vice President, Finance and Corporate Controller.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1880438/000119312523230786/0001193125-23-230786-index.htm
- Executive change
  Michael Nazak departed as Vice President, Corporate Controller at AN2 Therapeutics, Inc..
  - Action: will depart
  - Role: Vice President, Corporate Controller
  source text: Michael Nazak, Vice President, Corporate Controller and the prior Principal Accounting Officer, will depart the Company effective September 15, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1880438/000119312523230786/0001193125-23-230786-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.